Isomorphic Labs , a UK-based spinoff of DeepMind , announced it will soon enter human trials with drugs designed by its AlphaFold-based AI. The company, founded in 2021, leverages DeepMind 's AlphaFold 2 and the newer AlphaFold 3, which in 2024 advanced protein modeling to include DNA and RNA interactions, a breakthrough that earned the developers the Nobel Prize in chemistry . Isomorphic Labs raised $600 million in its first funding round and has formed partnerships with Eli Lilly and Novartis to pursue AI drug discovery. The AlphaFold platform has predicted the structures of 200 million proteins and is used by more than 2 million researchers from 190 countries. President Max Jaderberg said the company is "gearing up to go into the clinic" and that the molecules "can be taken at a much lower dose, with lower side effects." He added that the team's work "has engineered the molecules to be very potent." DeepMind co-founder Demis Hassabis noted that AlphaFold 3 "is exactly what you need for drug discovery" because it shows how small molecules bind to proteins. The company's chief medical officer said the mission is "a crazy mission" but they mean it.